Abstracts tagged "Infection"

Abstract Number: 784 • 2018 ACR/ARHP Annual Meeting
Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE
Pablo Castaño-Gonzalez¹, Mauricio Restrepo-Escobar^1,2, Laura Morales-Maya¹, Tomás Urrego¹, Simon Sandoval-Alvares¹, Carlos Horacio Muñoz^1,3, Adriana L Vanegas^1,3, Daniel Jaramillo^1,4, Gloria Vasquez¹ and Luis Gonzalez-Naranjo¹, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellin, Colombia, ²Hospital Universitario Pablo Tobon Uribe, Medellin, Colombia, ³Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁴Hospital Universitario de San Vicente Fundación, Medellin, Colombia
Background/Purpose: Patients with SLE have an increased risk of serious infections, including nosocomial infections, which are associated with potentially modifiable adverse outcomes. Our objective is…
Abstract Number: 2450 • 2018 ACR/ARHP Annual Meeting
Prosthetic Joint Infection in Patients with Rheumatoid Arthritis
John Fredy Jaramillo Gallego¹, Aurelia Luissi¹, Marina Scolnik², Javier Rosa¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Patients with rheumatoid arthritis (RA) have been shown to have an increased susceptibility to the development of prosthetic joint infection (PJI) after Total Hip…
Abstract Number: 942 • 2018 ACR/ARHP Annual Meeting
Risk of Serious Infections in Tocilizumab Versus TNF Inhibitor Initiators in Patients with RA: A Multi-Database Cohort Study
Ajinkya Pawar¹, Rishi J. Desai², Daniel Solomon¹, Sara Gale³, Min Bao⁴, Khaled Sarsour³, Sebastian Schneeweiss¹ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴Roche Innovation Center, New York, NY
Background/Purpose: While biologics are known to be associated with risk of serious infections, data on head-to-head comparison of different biologic drugs for the risk of…
Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Susan M. Goodman¹, Bo Shopsin², Allina A. Nocon¹, Andy O. Miller³, Michael W. Henry³, Sarah E. Grond¹, Elianna Kaplowitz¹, Thomas P. Sculco⁴, Linda A. Russell³, Laura T. Donlin⁵, Mark P. Figgie⁴ and Peter K. Sculco⁴, ¹Hospital for Special Surgery, New York, NY, ²Medicine and Microbiology, New York University School of Medicine, New York, NY, ³Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection than patients with osteoarthritis (OA). Disease modifying therapy is widely used…
Abstract Number: 1220 • 2018 ACR/ARHP Annual Meeting
The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis
Lior Nissim¹, Mary Louise Fowler², Robert Shmerling³, Sarah Lieber⁴, Mohammad Naffaa⁵ and Ziv Paz^4,5, ¹Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, ²Boston University School of Medicine, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Galilee Medical Center, Nahariya, Israel
Background/Purpose: Approximately 20,000 cases of septic arthritis (SA) occur in the United States each year with 2-10 cases per 100,000 person-years in the general population.…
Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting
Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
Maria Martin-Lopez¹, Eliseo Albert², Esther Rodriguez-Almaraz³, Isidoro Gonzalez-Alvaro⁴, Mario Fernandez-Ruiz⁵, Jose M. Aguado⁵, David Navarro² and Jose L. Pablos⁶, ¹Rheumatology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ²Microbiology, Instituto de Investigación INCLIVA, Hospital Clínico, Valencia, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre. Unit of Infectious Diseases, Madrid, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain, Madrid, Spain
Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…
Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Shubha Kollampare¹, C. Kent Kwoh^1,2, Wei-Hsuan Lo-Ciganic³, Lili Zhou^2,4, Erin L. Ashbeck² and Dominick Sudano¹, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ⁴College of Pharmacy, University of Arizona, Tucson, AZ
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
Abstract Number: 2614 • 2018 ACR/ARHP Annual Meeting
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Ori Elkayam¹, Devy Zisman², Ilana Kaufman³, Uri Arad⁴, Mark Berman⁵, Victoria Furer⁶, Yael Lahat¹, Or Carmi¹, Amir Haddad⁷, Muna Elias⁷, Daphna Paran¹ and Michal Mandelbaum⁸, ¹Department of rheumatology, Tel Aviv medical center and the Sackler Faculty of medicine, Tel Aviv University, Tel Aviv, Israel, ²Technion, Rheumatology Unit Carmel Medical Center, Haifa, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁷Rheumatology Unit Carmel Medical Center, Haifa, Israel, ⁸Sheba medical center, Ramat Gan, Israel
Background/Purpose: The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines…
Abstract Number: 1228 • 2018 ACR/ARHP Annual Meeting
Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study
Géraldine Bart¹, Guillaume Coiffier², Oriane Merot³, Emmanuel Hoppe⁴, Marion Couderc⁵, Denis Mulleman⁶, Gregoire Cormier⁷, Jean Marc Ziza⁸ and Benoit Le Goff¹, ¹Rheumatology, Nantes University Hospital, Nantes, France, ²Rheumatology, Rennes University Hospital, Rennes, France, ³rheumatology unit, Saint Nazaire Hospital, Saint Nazaire, France, ⁴Angers University Hospital, Angers, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Université François-Rabelais de Tours, CNRS 7292, Tours, France, ⁷Service de Rhumatologie, CHD de la Roche-Sur-Yon, La Roche-Sur-Yon, France, ⁸Medecine Interne-Rhumatologie, Groupe hospitalier Diaconesses-Croix-Saint-Simon, Paris, France
Background/Purpose: In a previous work, we showed that neurological complication can occur in up to 40% of patients with vertebral osteomyelitis (VO). Bed rest and…
Abstract Number: 2717 • 2018 ACR/ARHP Annual Meeting
Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon³, Loïc Guillevin³ and Benjamin Terrier⁹, ¹Medecine Interne, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, ⁵Department of Internal Medicine, CHU de Nantes, France, Nantes, France, ⁶Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, Paris, France, ⁷Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁸Internal Medicine, Foch, Suresnes, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Although overall survival of patients with systemic necrotizing vasculitides (SNVs) has improved markedly over the last 20 years, infectious complications remain a major cause…
Abstract Number: 1229 • 2018 ACR/ARHP Annual Meeting
Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis
Serene Z. Mirza¹, Shawn Richardson², Cynthia Kahlenberg², Jason Blevins², Michelle Demetres³, Lily Martin³, Jackie Szymonifka², Peter K. Sculco⁴, Mark P. Figgie⁵ and Susan M. Goodman², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Surgery, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with inflammatory arthritis (IA) are at increased risk of prosthetic joint infections, yet differentiating between septic and aseptic failure is a challenge in…
Abstract Number: 2832 • 2018 ACR/ARHP Annual Meeting
Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Sheng-Xiao Zhang¹, Xiao-Yan Wu², Jing Luo³, Guang-Ying Liu², Chong Gao⁴, Cai-Hong Wang⁵ and Xiao-Feng Li⁵, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁵The Second Hospital of Shanxi Medical Univerity, Taiyuan, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of intrinsic or adaptive immune system…
Abstract Number: 1231 • 2018 ACR/ARHP Annual Meeting
Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS
Jorge Juan Fragio Gil¹, Roxana Gonzalez Mazario¹, Francisco Miguel Ortiz-Sanjuán¹, Jose Ivorra Cortes¹, Elena Grau Garcia¹, Karla Arevalo¹, Isabel Martinez Cordellat¹, Inmaculada Chalmeta Verdejo¹, Jose Eloy Oller Rodriguez¹, Luis Gonzalez Puig¹, Marta De la Rubia Navarro¹, Rosa Negueroles Albuixech¹, Cristina Alcañiz Escandell², Elvira Vicens Bernabeu¹, Eva Calabuig³, Maria Tasias Pitarch³, Miguel Salavert Lleti³ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²IIS La Fe, Valencia, Spain, ³Infectious Diseases Unit. Hospital Universitario y Politecnico La Fe, Valencia, Spain
Background/Purpose: Vertebral Osteomyelitis is an infectious disease of the vertebral body which could involve the intervertebral space (spondylodiscitis). Early diagnosis and treatment are essential in…
Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Sarah L. Patterson¹, Michael Evans², Ishita Aggarwal³, Zara Izadi⁴, Milena Gianfrancesco⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California - San Francisco, San Francisco, CA, ³Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶San Francisco VA Medical Center, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
Abstract Number: 218 • 2018 ACR/ARHP Annual Meeting
Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Rishi J. Desai³, Angela Tong¹ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Treatment with tumor necrosis factor inhibitor (TNFi) with methotrexate or triple therapy (MTX, sulfasalazine, and sulfasalazine) is considered in patients with rheumatoid arthritis (RA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].